Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

September 24, 2026 updated by: Corcept Therapeutics

A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)

The primary objectives of this study are to evaluate progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS) (evaluated independently, as dual primary endpoints) in patients treated with intermittent regimen of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel monotherapy.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

As there are no currently approved therapies or effective standard of care for heavily pretreated patients with ovarian cancer who have exhausted single-agent chemotherapy and/or bevacizumab, the combination of intermittently administered relacorilant and nab-paclitaxel may demonstrate a substantial improvement without increased toxicity compared with nab-paclitaxel.

Patients will receive study treatment until confirmed progressive disease (PD) or unacceptable toxicity. All patients will be followed for the collection of study endpoints, inclusive of disease progression and survival.

Study Type

Interventional

Enrollment (Actual)

381

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Buenos Aires
      • CABA, Buenos Aires, Argentina, C1280AEB
        • Site 393
      • Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina, C1426ANZ
        • Site 381
    • Córdoba Province
      • Córdoba, Córdoba Province, Argentina, X5004FHP
        • Site 415
      • Córdoba, Córdoba Province, Argentina, X5008 HHW
        • Site 401
      • Córdoba, Córdoba Province, Argentina, X5016
        • Site 395
    • Mendoza Province
      • Mendoza, Mendoza Province, Argentina, M5500AYB
        • Site 404
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentina, 2000
        • Site 391
      • Rosario, Santa Fe Province, Argentina, S2000KDS
        • Site 412
    • New South Wales
      • St Leonards, New South Wales, Australia, 2065
        • Site 426
    • Queensland
      • Benowa, Queensland, Australia, 4217
        • Site 417
    • Victoria
      • Melbourne, Victoria, Australia, 3000
        • Site 414
      • Melbourne, Victoria, Australia, 3128
        • Site 419
      • Aalst, Belgium, 9300
        • Site 328
      • Brussels, Belgium, B- 1200
        • Site 109
      • Charleroi, Belgium, 6000
        • Site 326
      • Hasselt, Belgium, 3500
        • Site 325
      • Leuven, Belgium, 3000
        • Site 108
      • Liège, Belgium, B-4000
        • Site 327
      • Porto Alegre, Brazil, 90035-001
        • Site 421
    • Brasília - DF
      • Brasília, Brasília - DF, Brazil, 70297-400
        • Site 424
    • Ceará
      • Fortaleza, Ceará, Brazil, 60170-170
        • Site 382
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brazil, 41950-640
        • Site 384
    • Minas Gerais
      • Belo Horizonte, Minas Gerais, Brazil, 30210-040
        • Site 383
    • Rio Grande do Norte
      • Natal, Rio Grande do Norte, Brazil, 59062-000
        • Site 390
    • Rio de Janeiro
      • Rio de Janeiro, Rio de Janeiro, Brazil, 22250-905
        • Site 380
    • São Paulo
      • São Paulo, São Paulo, Brazil, 01321001
        • Site 376
      • São Paulo, São Paulo, Brazil, 01327-001
        • Site 389
      • São Paulo, São Paulo, Brazil, 01409-002
        • Site 413
      • São Paulo, São Paulo, Brazil, 01509-900
        • Site 374
      • São Paulo, São Paulo, Brazil, 01509010
        • Site 001
    • Ontario
      • Toronto, Ontario, Canada, M4N 3M5
        • Site 117
    • Quebec
      • Montreal, Quebec, Canada, H4A 3J1
        • Site 273
      • Lille, France, 59020
        • Site 306
      • Montpellier, France, 34298
        • Site 347
      • Nancy, France, 54100
        • Site 307
      • Nice, France, 06189
        • Site 310
      • Paris, France, 75015
        • Site 289
      • Plérin, France, 22190
        • Site 323
      • Budapest, Hungary, 1122
        • Site 322
      • Debrecen, Hungary, 4032
        • Site 290
      • Győr, Hungary, 9024
        • Site 348
      • Haifa, Israel, 3436212
        • Site 309
      • Jerusalem, Israel, 911201
        • Site 080
      • Tel Aviv, Israel, 6423906
        • Site 203
      • Catania, Italy, 95126
        • Site 321
      • Legnago, Italy, 37045
        • Site 320
      • Milan, Italy, 20141
        • Site 122
      • Pavia, Italy, 27100
        • Site 295
      • Roma, Italy, 161
        • Site 161
      • Rome, Italy, 00168
        • Site 124
      • Torino, Italy, 10128
        • Site 293
      • Treviso, Italy, 31100
        • Site 319
      • Gdynia, Poland, 81-519
        • Site 341
      • Poznan, Poland, 61-886
        • Site 331
      • Siedlce, Poland, 08-110
        • Site 329
      • Gyeonggi-do, South Korea, 10408
        • Site 397
      • Seoul, South Korea, 03080
        • Site 399
      • Seoul, South Korea, 03722
        • Site 398
      • Seoul, South Korea, 05505
        • Site 403
      • Seoul, South Korea, 06273
        • Site 400
      • Seoul, South Korea, 06351
        • Site 396
      • Seoul, South Korea, 08308
        • Site 402
      • Seoul, South Korea, 42601
        • Site 409
      • Badalona, Spain, 08916
        • Site 349
      • San Sebastián, Spain, 20014
        • Site 311
      • Valencia, Spain, 46026
        • Site 330
      • Cheltenham, United Kingdom, GL53 7AN
        • Site 366
      • London, United Kingdom, NW1 2PG
        • Site 055
      • Manchester, United Kingdom, M20 4BX
        • Site 344
      • Northwood, United Kingdom, HA6 2RN
        • Site 345
    • East Sussex
      • Brighton, East Sussex, United Kingdom, BN2 1ES
        • Site 367
    • Somerset
      • Taunton, Somerset, United Kingdom, TA1 5DA
        • Site 351
    • Arizona
      • Phoenix, Arizona, United States, 85016
        • Site 318
      • Tucson, Arizona, United States, 85719
        • Site 277
    • California
      • Irvine, California, United States, 92618
        • Site 350
      • La Jolla, California, United States, 92093
        • Site 364
      • Palo Alto, California, United States, 94304
        • Site 150
      • San Francisco, California, United States, 94109
        • Site 278
      • San Francisco, California, United States, 94143
        • Site 014
      • Solvang, California, United States, 93463
        • Site 316
    • Colorado
      • Aurora, Colorado, United States, 80045
        • Site 032
    • Florida
      • Miami Beach, Florida, United States, 33140
        • Site 335
      • Weston, Florida, United States, 33331
        • Site 042
    • Georgia
      • Atlanta, Georgia, United States, 30322
        • Site 009
      • Atlanta, Georgia, United States, 30342
        • Site 272
      • Gainesville, Georgia, United States, 30548
        • Site 372
      • Savannah, Georgia, United States, 31405
        • Site 291
    • Illinois
      • Evanston, Illinois, United States, 60201
        • Site 315
      • Hinsdale, Illinois, United States, 60521
        • Site 314
      • Urbana, Illinois, United States, 61801
        • Site 346
    • Indiana
      • Indianapolis, Indiana, United States, 46260
        • Site 339
    • Kansas
      • Overland Park, Kansas, United States, 66211
        • Site 200
      • Overland Park, Kansas, United States, 66211
        • Site 334
    • Kentucky
      • Louisville, Kentucky, United States, 40241
        • Site 279
    • Massachusetts
      • Boston, Massachusetts, United States, 02114
        • Site 128
    • New Jersey
      • New Brunswick, New Jersey, United States, 08901
        • Site 288
    • New Mexico
      • Albuquerque, New Mexico, United States, 87131
        • Site 292
    • New York
      • Flushing, New York, United States, 11355
        • Site 275
    • Ohio
      • Cincinnati, Ohio, United States, 45242
        • Site 298
      • Cincinnati, Ohio, United States, 45459
        • Site 304
    • Oregon
      • Portland, Oregon, United States, 97210
        • Site 280
      • Portland, Oregon, United States, 97213
        • Site 317
      • Portland, Oregon, United States, 97239
        • Site 049
    • Pennsylvania
      • Bethlehem, Pennsylvania, United States, 18015
        • Site 337
      • Pittsburgh, Pennsylvania, United States, 15213
        • Site 127
    • South Dakota
      • Rapid City, South Dakota, United States, 57701
        • Site 276
    • Tennessee
      • Germantown, Tennessee, United States, 38138
        • Site 368
      • Nashville, Tennessee, United States, 37203
        • Site 281
    • Texas
      • Austin, Texas, United States, 78731
        • Site 229
      • Bedford, Texas, United States, 76022
        • Site 312
      • Fort Worth, Texas, United States, 76104
        • Site 297
      • San Antonio, Texas, United States, 78240
        • Site 392
      • The Woodlands, Texas, United States, 77380
        • Site 301
    • Virginia
      • Norfolk, Virginia, United States, 23502
        • Site 300
      • Richmond, Virginia, United States, 23298
        • Site 365
    • Wisconsin
      • Milwaukee, Wisconsin, United States, 53226
        • Site 121

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Signed and dated Institutional Review Board/Independent Ethics Committee-approved informed consent form prior to study-specific screening procedures.
  • Confirmed histologic diagnosis of high-grade (Grade 3) serous, epithelial ovarian, primary peritoneal, or fallopian tube carcinoma.
  • Patients must have platinum-resistant disease (defined as RECIST v1.1 defined progression <6 months from completion of a platinum-containing therapy).
  • Must consent to provide archival tumor-tissue block or slides. Patients may consent to an optional tumor biopsy if archival tumor is unavailable.
  • Has a life expectancy of ≥3 months.
  • At least one lesion that meets the definition of measurable disease by RECIST v1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
  • Able to comply with protocol requirements.
  • Able to swallow and retain oral medication and does not have uncontrolled emesis.
  • Received at least 1 but ≤3 lines of prior systemic anticancer therapy and at least 1 prior line of platinum therapy and prior treatment with bevacizumab is required.
  • Has adequate organ function meeting the following laboratory-test criteria: Absolute neutrophil count (ANC) ≥1500 cells/mm^3, Platelet count ≥100,000/mm^3, Hemoglobin ≥9 g/dL, Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤2.5 × upper limit of normal (ULN), or ≤5 × ULN in context of liver metastases, Total bilirubin ≤1.5 × ULN, and Albumin ≥3 g/dL, and creatinine clearance >40 mL/min/1.73 m^2 (measured or estimated).
  • Negative pregnancy test for patients of childbearing potential; patients of childbearing potential must agree to use highly effective contraceptive method(s); hormonal contraceptives are not allowed.
  • Coronavirus disease (COVID-19) approved vaccines are accepted concomitant medications when recommended by the Investigator.

Exclusion Criteria:

  • Has clinically relevant toxicity from prior systemic anticancer therapies or radiotherapy that has not resolved to ≤Grade 1 prior to randomization.
  • Has had any major surgery within 4 weeks prior to randomization.
  • Has low-grade endometrioid, clear cell, mucinous, or sarcomatous histology, or mixed tumors containing any of these histologies, or low-grade or borderline ovarian tumor.
  • Has primary platinum-refractory disease, defined as disease that did not respond to or has progressed ≤1 month of the last dose of first-line platinum-containing chemotherapy.
  • Has not received prior bevacizumab treatment.
  • Has been treated with the following prior to randomization: chemotherapy, immunotherapy, investigational agent treatments for disease under study within 28 days before first dose of study drug, radiotherapy not completed at least 2 weeks prior to first dose of study drug, hormonal anticancer therapies within 7 days of first dose of study drug, and systemic, inhaled, or prescription strength topical corticosteroids within 21 days of first dose of study drug.
  • Has received wide-field radiation to more than 25% of marrow-bearing areas.
  • Has toxicities of prior therapies that have not resolved by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0, ≤Grade 1.
  • Requires treatment with chronic or frequently used oral corticosteroids for medical conditions or illnesses.
  • Has a history of severe hypersensitivity or severe reaction to any of the study drugs.
  • Is receiving concurrent treatment with mifepristone or other glucocorticoid receptor (GR) modulators.
  • Has peripheral neuropathy from any cause >Grade 1.
  • Pregnant or lactating patients or patients expecting to conceive children within the projected duration of the trial, starting with the screening visit through at least 1 month after the last dose of relacorilant, or 6 months after the last dose of nab-paclitaxel whichever is the longest.
  • Has clinically significant uncontrolled condition(s) or condition which, in the opinion of the Investigator, may confound the results of the trial or interfere with the patient's safety or participation.
  • Has current chronic/active infection with human immunodeficiency virus or current chronic/active infection with hepatitis C virus or hepatitis B virus.
  • Has any untreated or symptomatic central nervous system (CNS) metastases.
  • Patients with a history of other malignancy within 3 years prior to randomization.
  • Is taking a concomitant medication that is a strong cytochrome P450 (CYP)3A inhibitor or strong CYP3A inducer, or that is a substrate of CYP3A with a narrow therapeutic window.
  • Concurrent treatment on other investigational treatment studies for the treatment of ovarian, fallopian tube, or primary peritoneal cancer.
  • Has received a live vaccine within 30 days prior to the study start date.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Relacorilant 150 mg With Nab-paclitaxel 80 mg/m^2

Patients receive nab-paclitaxel 80 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle in combination with intermittent relacorilant (150 mg relacorilant once daily on the day before, the day of, and the day after nab-paclitaxel), administered orally under fed conditions. Relacorilant will not be administered on Cycle 1 Day -1.

Relacorilant is administered as capsules for oral dosing once daily on the day before, the day of, and the day after nab-paclitaxel administration.

Other Names:
  • Lifyorli

Nab-paclitaxel is administered as intravenous (IV) infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle.

Active Comparator: Nab-paclitaxel 100 mg/m^2

Patients receive nab-paclitaxel 100 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle.

Nab-paclitaxel is administered as IV infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)
Time Frame: Up to 20 months

PFS was assessed as the time from randomization until the time of first documented progressive disease (PD) or death due to any cause, whichever occurs first. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or an unequivocal progression in a non-target lesion, or the appearance of new lesions.

Up to 20 months
Overall Survival
Time Frame: Up to 32 months

Overall survival (OS) was assessed as the time from randomization to death by any cause. The data values are Kaplan-Meier estimates.

Up to 32 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PFS as Assessed by the Investigator
Time Frame: Up to 20 months

PFS was assessed as the time from randomization until the time of first documented progressive disease (PD) by RECIST v1.1, or death due to any cause, whichever occurs first.

Up to 20 months
Objective Response as Assessed by the Investigator
Time Frame: Up to 20 months

Objective response was assessed as the proportion of patients with measurable disease at baseline who attained complete response (CR) or partial response (PR). Confirmation of the response was not required for this outcome measure per RECIST v1.1 criteria for randomized controlled clinical trials. Responses were assessed by imaging, using RECIST v1.1 criteria for target lesions: CR, Disappearance of all target lesions; PR, ≥30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Up to 20 months
Best Overall Response as Assessed by the Investigator
Time Frame: Up to 20 months

Best overall response was assessed as the proportion of patients with at least 1 post Baseline scan who attained CR, PR, stable disease (SD), or PD as best response by RECIST v1.1.

Up to 20 months
Duration of Confirmed Responses as Assessed by the Investigator
Time Frame: From the time of confirmed CR or PR to the time of the first PD or death (Up to 18 months)

The median duration of response is presented for confirmed responses (CR or PR) per RECIST v1.1. Duration of response was from the first documented and confirmed response to the first objectively documented PD as assessed by the Investigator, or death due to any cause, whichever occurs first.

From the time of confirmed CR or PR to the time of the first PD or death (Up to 18 months)
Clinical Benefit Rate at 24 Weeks as Assessed by BICR and the Investigator
Time Frame: 24 weeks

Clinical benefit rate was assessed as the proportion of patients who attained CR, PR, or stable disease (SD) for 24 weeks per RECIST v1.1 as assessed by BICR and as assessed by the Investigator.

24 weeks
Cancer Antigen (CA)-125 Response
Time Frame: Up to 24 months

CA-125 response was assessed per Gynecologic Cancer Intergroup (GCIG) criteria defined as ≥50% reduction in CA-125 from a pretreatment sample and maintained for ≥28 days in patients with a pretreatment sample that is at least twice the upper limit of the reference range within 2 weeks before starting the treatment. In addition, patients who have a CA-125 response and whose CA-125 level fell to within the reference range were classified as CA-125 complete responders.

Up to 24 months
Combined Overall Response Rate by RECIST v1.1 and CA-125 Defined by GCIG Criteria
Time Frame: Up to 15 months

Combined response was assessed as the proportion of patients with tumor response per RECIST v1.1 assessed by the investigator and for CA-125 response per GCIG criteria.

Up to 15 months
Number of Patients With One or More Adverse Events
Time Frame: Up to 22 months
Up to 22 months
Number of Patients Who Discontinued the Study Treatment Due to an Adverse Event
Time Frame: Up to 25 months
Up to 25 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Study Director: Adrian Jubb, MBChB, PhD, FRCPath, Corcept Therapeutics

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 29, 2022

Primary Completion (Actual)

March 31, 2025

Study Completion (Estimated)

December 1, 2026

Study Registration Dates

First Submitted

February 4, 2022

First Submitted That Met QC Criteria

February 16, 2022

First Posted (Actual)

February 25, 2022

Study Record Updates

Last Update Posted (Actual)

September 25, 2026

Last Update Submitted That Met QC Criteria

September 24, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • CORT125134-556
  • GOG-3073 (Other Identifier: Gynecologic Oncology Group)
  • ROSELLA Study 556 (Other Identifier: Corcept Therapeutics)
  • ENGOT-OV72 (Other Identifier: European Network of Gynaecological Oncological Trial Groups)
  • APGOT-Ov10 (Other Identifier: Asia-Pacific Gynecologic Oncology Trials Group)
  • LACOG 0223 (Other Identifier: Latin American Cooperative Oncology Group)
  • ANZGOG2221/2023 (Other Identifier: Australia New Zealand Gynaecological Oncology Group)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.